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Abstract
Aims New generation dual-source coronary CT (NGCCT)
scanners with more than 64 slices were evaluated for
patients with (known) or suspected of coronary artery
disease (CAD) who are difficult to image: obese, coronary
calcium score[ 400, arrhythmias, previous revasculariza-
tion, heart rate[ 65 beats per minute, and intolerance of
betablocker. A cost-effectiveness analysis of NGCCT
compared with invasive coronary angiography (ICA) was
performed for these difficult-to-image patients for England
and Wales.
Methods and results Five models (diagnostic decision
model, four Markov models for CAD progression, stroke,
radiation and general population) were integrated to esti-
mate the cost-effectiveness of NGCCT for both suspected
and known CAD populations. The lifetime costs and
effects from the National Health Service perspective were
estimated for three strategies: (1) patients diagnosed using
ICA, (2) using NGCCT, and (3) patients diagnosed using a
combination of NGCCT and, if positive, followed by ICA.
In the suspected population, the strategy where patients
only undergo a NGCCT is a cost-effective option at
accepted cost-effectiveness thresholds. The strategy of
using NGCCT in combination with ICA is the most
favourable strategy for patients with known CAD. The
most influential factors behind these results are the per-
centage of patients being misclassified (a function of both
diagnostic accuracy and the prior likelihood), the compli-
cation rates of the procedures, and the cost price of a
NGCCT scan.
Conclusion The use of NGCCT might be considered cost-
effective in both populations since it is cost-saving com-
pared to ICA and generates similar effects.
Keywords Cost-effectiveness  CT scanner  Coronary
artery disease  Radiation  ImagingElectronic supplementary material The online version of this
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Introduction
In recent years imaging technologies have been developed
rapidly, leading to the introduction of new generation
coronary computed tomography (NGCCT) scanners. The
latest generation of dual-source instruments may have a
significant benefit over the current technologies, especially
for difficult-to-image patients through improvements in
image quality, and reductions in the scan duration and
radiation exposure.
Currently, for patients suspected of coronary artery
disease (CAD) the diagnosis is usually based on tests such
as an invasive coronary angiography (ICA), functional
imaging, computed tomography (CT) coronary angiogra-
phy (CTCA), or a computed tomography calcium scoring.
The appropriate diagnostic test depends on the likelihood
of having CAD as described in the NICE clinical guide-
line [1]. If the likelihood of CAD is between 10 and 90 %
then a patient will undergo further examination, i.e.
64-slice CT for the patients with a likelihood between 10
and 29 %. In addition, these diagnostic tests can also be
used to decide whether a revascularization is necessary.
The performance of 64-slice CT for diagnosing CAD has
been well established. Recent systematic reviews have
estimated that 64-slice CT, for the detection of C50 %
coronary artery stenosis, is very accurate [2–4]. However,
64-slice CT cannot be (routinely) used for specific groups
of patients who are difficult to image due to decreased
image quality [5]. These include patients with: (1)
arrhythmias, (2) heart rate [ 65 beats per minute, (3)
obesity, (4) coronary calcium level[ 400, (5) a previous
coronary revascularization with a stent, (6) b-blocker
intolerance or (7) a previous coronary artery bypass graft
(CABG). In these difficult-to-image patients, ICA, a more
invasive diagnostic procedure, may therefore be indicated.
Newer generation CT instruments may provide an alter-
native to an ICA for these patients, and have a lower
procedure-related mortality and morbidity. One potential
disadvantage may be a slightly lower sensitivity and
specificity compared to ICA, which means a greater fre-
quency of false positive (FP) and false negative (FN)
results that may lead to incorrect treatment decisions,
health loss and increased costs. We performed a cost-
effectiveness study of the NGCCT compared with ICA
for difficult-to-image patients for England and Wales.
Methods
The lifetime cost-effectiveness of NGCCT for difficult-to-
image patient groups was estimated for two separate pop-
ulations: patients with suspected CAD and patients with
known CAD. The suspected CAD population includes
patients with chest pain or other symptoms suggestive of
CAD. Patients with known CAD were defined as patients
with a diagnosis of CAD whose symptoms are no longer
controlled with drug treatment and/or are being considered
for revascularization. The characteristics (e.g. age, systolic
blood pressure) of the difficult-to-image subgroups are
based on the studies that are included in a systematic
review [6]. The NGCCT has a different purpose in each
population. For the suspected population the purpose of
NGCCT is to diagnose CAD and, if present, a patient is
treated with revascularization or medication. For the
known population the purpose of NGCCT is to decide
whether a revascularization is necessary.
Strategies
Three strategies were examined: (1) a strategy where
patients only undergo an ICA (ICA–only strategy), (2) a
strategy where patients only undergo the NGCCT
(NGCCT–only strategy), and (3) a strategy where patients
are first assessed with NGCCT and undergo an ICA if the
NGCCT is positive (NGCCT–ICA strategy). NGCCTs are
defined as dual-source cardiac CT scanners with[64 slices
[Brilliance iCT (Phillips Healthcare), Somatom Definition
Flash (Siemens Healthcare), Aquilion ONE (Toshiba
Medical Systems), and Discovery CT750 HD (GE
Healthcare)].
Models
The cost-effectiveness analyses were conducted by com-
bining five models which were adjusted for this specific
decision problem: (1) a decision model of the diagnostic
pathway (diagnostic model) [7], (2) a Markov model
reflecting the prognosis of CAD patients [disease pro-
gression model (DPM) [8]], (3) a Markov model to esti-
mate the impact of radiation on cancer mortality and
morbidity [York Radiation Model (YRM) [6] [9]], (4) a
Markov model to account for mortality amongst persons
without CAD [general population model (GPM) [7]] and
(5) a Markov model was created by the authors to esti-
mate the impact of stroke due to the initial test and
treatment (stroke model). The diagnostic model (Figs. 1,
2), where the entire cohort of patients starts, splits the
cohort into separate subcohorts of patients based on prior
likelihood, treatment-dependent diagnostic performance
and complication rates. It determines whether the long-
term costs and effects are modelled through the DPM
(Fig. 3), GPM (Fig. 4) or the stroke model (Fig. 4). For
example, the prognosis of patients with a true positive
(TP) test and no stroke was modelled with the DPM while
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the prognosis of stroke patients was modelled using the
stroke model. The YRM (Fig. 5) provided disutilities and
costs due to radiation-induced cancer based on the radi-
ation dose of the diagnostic tests and treatments; this
model was applied to all patients undergoing the respec-
tive test or treatment. We then combined the results for
all of the different models (i.e. diagnostic, GPM, stroke,
YRM and DPM) to derive a complete cost-effectiveness
estimate for each specific difficult-to-image subgroup. In
conclusion, the diagnostic model and the YRM was used
for the entire cohort and the DPM, stroke and GPM were
used depending on the test result and complications
(Table 28 [6]). The aim of the study was to compare the
overall cost-effectiveness of the three strategies in each of
the two populations (suspected and known CAD). Expert
opinion (N = 4) from radiologists and cardiologists was
used to gather information on the relative frequencies of
patients (Tables 1, 2) in the difficult-to-image subgroups
in the known or suspected CAD population (appendix 7
[6]). Multiplication of the relative proportions with the
subgroup-specific costs and effects produced an overall
incremental cost-effectiveness ratio (ICER) for both
populations.
The analyses were based on cohort simulations. Costs
and effects were discounted at 3.5 %, and the study was
performed from a National Health Service perspective.
Model variables
Input parameters, based on published literature and expert
opinion, are provided as supplementary data in Table S1
and in the full report [6].
Transition probabilities
Prior likelihood, accuracy estimates of the tests and com-
plication rates of the procedures are important parameters
in the diagnostic model. The prior likelihood (20 %) of
having CAD in patients with suspected CAD was based on
the clinical guideline ‘‘Chest pain of recent onset’’ [1].
Patients with a prior likelihood of 20 % are normally
diagnosed with a 64-slice CT, the technology that the
Fig. 1 Diagnostic model for suspected CAD population. CAD
coronary artery disease, ICA invasive coronary angiography, NGCCT
new generation coronary computed tomography, TP true positive, FP
false positive, FN false negative, TN true negative, CABG coronary
artery bypass graft, PCI percutaneous coronary intervention, DPM
disease progression model
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NGCCT will replace for patients who are difficult to
image. The prior likelihood of performing a revascular-
ization in patients with known CAD was based on the CE-
MARC study [7] (Table S1). We used this estimate due to
lack of data despite the possibility that the CE-MARC
population may not perfectly match our population. The
sensitivity and specificity of ICA were assumed to be
100 %, as in Mowatt et al. [2]. The estimates of the sen-
sitivity and specificity for the NGCCT were based on a
systematic review which aimed to identify accuracy esti-
mates for all type of scanners [10]. This review found 21
studies evaluating the Somatom Definition Flash, one study
evaluating the Aquilion ONE and one study evaluating the
Discovery CT750 HD. In the remainder of the paper we
will assume that these accuracy estimates are generalizable
to other NGCCTs. Complication rates of ICA and the
procedures were based on West et al. [11], Tarakji et al.
[12], Serruys et al. [13], Rajani et al. [14], and Bridgewater
et al. [15].
The risks of cardiovascular events for patients with
CAD in the DPM were based on the results of the
EUROPA trial [8]. We used four equations to calculate: (1)
the probability of any event that will occur in one cycle of
3 months; (2) the probability that the event is fatal; (3) the
probability of a subsequent event in the first year after a
first non-fatal event and (4) the probability of a subsequent
event after 1 year. Tables 21–26, 44 and 45 from West-
wood et al. [6] present the input parameters and risk
equations that were used in the DPM.
Life expectancy for patients without CAD was based on
UK life tables [16]; the life expectancy for stroke patients
was derived by adjusting the UK life tables for excess
mortality risk based on an observational study of stroke
patients [17] (Table 33 [6]).
The adjusted version of the YRM models the harmful
consequences of radiation exposure. Based on age at
exposure, gender, and radiation dose (mSv) we have esti-
mated the probability of developing cancer. For patients
developing radiation-induced cancer, the remaining qual-
ity-adjusted life-years (QALYs) given the average age of
cancer incidence and the average treatment cost for cancer
are calculated [9] (Tables 47 and 52 [6]).
Fig. 2 Diagnostic model for known CAD population. CAD coronary
artery disease, ICA invasive coronary angiography, NGCCT new
generation coronary computed tomography, TP true positive, FP false
positive, FN false negative, TN true negative, CABG coronary artery
bypass graft, PCI percutaneous coronary intervention, DPM disease
progression model
L. T. Burgers et al.
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Costs
The costs of the three strategies included the cost of the
diagnostic tests, non-fatal events [myocardial infarction
(MI) and cardiac arrest], procedures (e.g. revasculariza-
tion), CAD management costs (e.g. medication), stroke-
related costs and costs due to radiation-induced cancer
(Table S1). Original cost prices were inflated to reflect
costs for 2010 using PSSRU Health Unit costs of Health
and Social Care 2010 [18].
The price of the NGCCT procedure was calculated using
a bottom-up costing since only data for CT in general (i.e.
not specifically for CTCA) was available (Table 30 [6]).
The costs occurring in the first year after a non-fatal car-
diovascular event, a fatal cardiovascular event, and a non-
cardiovascular fatal event were based on the EUROPA trial
[19]. For subsequent years after the non-fatal event, the
additional cost was estimated at £986 [8]. CAD
management costs for each difficult-to-image patient group
were calculated using a previously published regression
model, which estimates costs using patient characteristics
Fig. 3 Disease progression model. MI myocardial infarction, CA cardiac arrest, CV cardiovascular, Eq equation Adapted from Briggs et al. [8]
Fig. 4 Life-death model structure used for stroke model and GPM.
GPM general population model
Fig. 5 York radiation model. QALY quality adjusted life years
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such as age, diabetes mellitus, medication usage, and
symptomatic disease [8]. Tables 35–38 from Westwood
et al. [6] present the input parameters and risk equations
that were used in the DPM. Costs due to radiation-induced
cancer are based on a number of previous comprehensive
assessments of the economic burden of treating several
different types of cancer [9] (Table 46 [6]).
Health-related quality of life
The overall effectiveness of the three strategies was
expressed in QALYs. QALYs represent a combination of
life expectancy and health-related quality of life (HRQoL).
The HRQoL estimates of CAD patients were based on
three sources: UK population norms for the EQ5D [20]
(Table 34 [6]), EQ5D scores per Canadian Cardiovascular
Society class of angina pectoris [21] and treatment effect
on HRQoL based on the RITA2 trial [22] (Tables 39–42
[6]). These sources were used to calculate HRQoL for each
difficult-to-image group [7]. It was assumed that a non-
fatal event was associated with a disutility of 0.0102 for the
subsequent 3 months [23]. Loss in QALYs due to radia-
tion-induced cancer were based on the UK population [9]
(Tables 49 and 50 [6]). HRQoL of patients with stroke
were estimated to be 0.37 using the results of the study of
Sandercock et al. [17].
Assumptions
A number of assumptions were made in this study. First,
the ICA (‘‘gold standard’’) was assumed to have a sensi-
tivity and specificity of 100 %. Second, we assumed that
all diagnostic tests are performed immediately after each
other without any relevant time delay. Third, we also
assumed that the sensitivity and specificity of the tests for
each difficult-to-image subgroup are the same for both
populations. Lastly, the complication rates of revascular-
ization and ICA were assumed to be the same in all
Table 1 Cost-effectiveness of NGCCT for the suspected CAD population
Suspected CAD
population
Relative
proportionsa
Costs QALYs DCosts DQALYs ICER
(£/QALY)
Mean
(£)
SD Range
(2.5–97.5 %)
Mean SD Range
(2.5–97.5 %)
Overall
NGCCT–only 5808 573 4683–6901 10.588 0.109 10.377–10.806
NGCCT–ICA 5950 589 4825–7068 10.590 0.109 10.371–10.808 142 0.002 71,000
ICA–only 6534 572 5415–7642 10.597 0.107 10.385–10.797 584 0.007 83,429
Obese
NGCCT–ICA 16.25 % 6297 1237 4055–8976 10.508 0.167 10.173–10.829
NGCCT–only 6106 1202 3917–8695 10.508 0.167 10.159–10.824 -191 0.000 Dominates
NGCCT–ICA
ICA–only 6968 1217 4743–9629 10.519 0.163 10.183–10.830 862 0.011 81,318
Arrhythmias
NGCCT–ICA 11.75 % 6227 1190 4052–8706 9.419 0.171 9.073–9.748
NGCCT–only 6077 1161 3943–8494 9.42 0.171 9.073–9.740 -150 0.000 Dominates
NGCCT–ICA
ICA–only 6785 1205 4603–9367 9.448 0.166 9.112–9.761 708 0.029 24,645
Heart rate[ 65 bpm
NGCCT–only 29.25 % 6595 1256 4314–9287 10.967 0.156 10.642–11.258
NGCCT–ICA 6758 1289 4419–9511 10.968 0.157 10.651–11.266 162 0.001 312,047
ICA–only 7342 1263 5027–10041 10.969 0.155 10.660–11.255 584 0.001 440,057
Coronary calcium level[ 400
NGCCT–only 27.50 % 5962 1168 3872–8456 10.201 0.169 9.855–10.520
NGCCT–ICA 6142 1248 3973–8794 10.202 0.169 9.851–10.530 180 0.001 205,536
ICA–only 6801 1189 4711–9361 10.21 0.167 9.871–10.531 659 0.008 80,446
Intolerance b-blocker
NGCCT–ICA 15.25 % 6430 1320 4082–9209 11.54 0.151 11.235–11.830
ICA–only 7016 1242 4767–9576 11.541 0.148 11.242–11.824 586 0.001 972,803
NGCCT–only 6279 1240 4058–8850 11.542 0.151 11.234–11.828 -736 0.001 Dominant
a Expert opinion
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subgroups. The full set of assumptions is provided in
Westwood et al. [6].
Analyses
Base-case scenarios were based on a probabilistic sen-
sitivity analysis (PSA) due to the non-linearity of the
model. The PSA was performed by running a Monte
Carlo simulation of 5000 simulations of the model. In
the PSA, parameters were varied simultaneously using a
priori defined distributions. Gamma distributions were
used for costs, log-normal distributions for relative risks,
and beta distributions were used for utility values and
probabilities. In addition, a cost-effectiveness
Table 2 Cost-effectiveness of NGCCT for the known CAD population
Known CAD
population
Relative
proportionsa
Costs QALYs DCosts DQALYs ICER
(£/QALY)
Mean
(£)
SD Range
(2.5–97.5 %)
Mean SD Range
(2.5–97.5 %)
Overall
ICA–only 28,234 502 27,262–29,240 9.516 0.288 8.959–10.066
NGCCT–ICA 27,785 531 26,785–28,786 9.537 0.283 8.986–10.081 -449 0.022 Dominates
ICA–only
NGCCT–only 28,228 498 27,269–29,217 9.538 0.286 8.986–10.081 443 0.001 726,230
Obese
ICA–only 10 % 29,694 928 27,973–31,562 8.857 0.464 7.823–9.674
NGCCT–only 29,254 924 27,538–31,130 8.869 0.477 7.800–9.707 -439 0.012 Dominates
ICA–only
NGCCT–ICA 29,177 920 27,465–31,024 8.872 0.46 7.891–9.700 -77 0.003 Dominant
Arrhythmias
ICA–only 7.33 % 27,428 908 25,625–29,232 6.545 0.504 5.507–7.480
NGCCT–ICA 27,084 916 25,316–28,912 6.588 0.503 5.552–7.523 -344 0.043 Dominates
ICA–only
NGCCT–only 27,726 971 25,833–29,660 6.595 0.499 5.565–7.507 642 0.007 90,683
Heart rate[ 65 bpm
ICA–only 27.33 % 30,434 1169 28,219–32,764 11.223 0.381 10.400–11.894
NGCCT–only 30,477 1190 28,226–32,927 11.233 0.377 10.424–11.906 43 0.011 4021
NGCCT–ICA 30,080 1184 27,853–32,486 11.242 0.378 10.429–11.903 -397 0.009 Dominant
Coronary calcium level[ 400
ICA–only 25.67 % 31,145 1079 29,054–33,300 9.271 0.538 8.155–10.216
NGCCT–only 30,839 1103 28,753–33,092 9.301 0.533 8.201–10.288 -306 0.03 Dominates
ICA–only
NGCCT–ICA 30,661 1075 28,643–32,861 9.306 0.539 8.138–10.259 -178 0.005 Dominant
Intolerance b-blockers
ICA–only 9.33 % 29,339 986 27,478–31,345 10.016 0.392 9.188–10.720
NGCCT–only 29,354 1004 27,446–31,377 10.039 0.392 9.206–10.746 14 0.024 610
NGCCT–ICA 28,972 988 27,121–30,976 10.042 0.394 9.185–10.740 -381 0.003 Dominant
Previous stent
ICA–only 11 % 28,450 842 26,828–30,082 8.724 0.364 7.944–9.370
NGCCT–ICA 28,056 855 26,413–29,690 8.737 0.358 7.960–9.371 -394 0.013 Dominates
ICA–only
NGCCT–only 28,672 888 26,972–30,406 8.744 0.354 7.986–9.381 617 0.007 93,526
Previous CABG
ICA–only 9.33 % 28,466 844 26,852–30,152 8.719 0.363 7.935–9.374
NGCCT–ICA 28,088 859 26,458–29,797 8.725 0.36 7.963–9.389 -378 0.006 Dominates
ICA–only
NGCCT–only 28,554 1028 26,682–30,723 8.725 0.359 7.956–9.382 466 0 2,943,850
a Expert opinion
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acceptability curve (CEAC) was created to present the
probability of the diagnostic tests being cost-effective at
varying willingness-to-pay thresholds. Scenario analyses
were performed to determine the impact of different
values for the input parameters on the ICERs. The cost
price of the NGCCT, the prior likelihood of CAD in the
suspected population, and the complication rates were
varied. The cost price of NGCCT was fixed at £150 for
the lower limit and at £207 for the upper limit; this
range was based on the bottom-up costing method where
we varied the number of procedures performed per year.
The prior likelihood of the suspected population was
increased to 0.3, which was the upper limit of the range
when a 64-slice CT should be performed to diagnose
patients suspected of CAD [1]. Worst-case and best-case
scenarios for the NGCCT strategies were performed by
varying the complication rates (lower and upper limits of
95 % confidence interval) of a revascularization and of
the test. Moreover, cost-effectiveness acceptability
curves were created to present the probability of a
strategy being cost-effective given the willingness-to-pay
threshold. Currently, NICE applies a threshold of
£20,000–£30,000 per QALY gained [24]. More infor-
mation concerning the modelling methods and input
parameters can be found in Westwood et al. [6]. All
analyses were performed using Microsoft Excel 2010.
Results
The base-case results, reflecting a frequency-weighted
average of the results of the different subgroups, revealed
that NGCCT was initially less expensive than ICA, but that
the lower sensitivity and specificity of NGCCT leads to
more incorrect diagnostic classifications (Table 3). Fur-
thermore, the NGCCT reduces radiation-induced cancer,
complications (stroke and MI) and mortality due to the
diagnostic procedure compared with ICA. An overall
QALY estimate and a separate QALY estimate per model
for every strategy, subgroup and population are in
Tables 57 and 58 in Westwood et al. [6].
Suspected CAD population
Table 1 presents the overall costs and effects for the sus-
pected CAD population and the cost and effects per diffi-
cult-to-image subgroup. The strategies are arranged
according to increasing effectiveness and ICERs are esti-
mated for the two most effective strategies by comparing
the strategies with the strategy that is ranked lower in
effectiveness.
The three strategies differed very little in their
effectiveness; the ICA–only strategy was only slightly
more effective than the other strategies (i.e. 10.597
QALYs vs 10.590 QALYs for NGCCT–ICA and 10.588
for NGCCT–only). However, the ICA–only strategy was
also the most expensive strategy (£6534), followed by
NGCCT–ICA (£5950) and the NGCCT–only strategy
(£5808). The NGCCT–only strategy might be considered
as a cost-effective strategy, since its effectiveness is very
similar to that of the ICA–only strategy and its overall
costs are lower than that of the other strategies. The
ICER of NGCCT–ICA versus NGCCT–only is consid-
erably higher (£71,000) than the currently used threshold
of £20,000–£30,000 per additional QALY. The ICA–
only strategy generated the most effects but was also the
most expensive strategy leading to an ICER that would
exceed the threshold (£83,429). The subgroups analyses
correspond with the overall results; however, ICA–only
is the most cost-effective strategy for patients with
arrhythmias (ICER: £24,645) if a threshold of £30,000
per additional QALY is used. Figure 6 shows a cost-
effectiveness acceptability curve; the NGCCT–only
strategy has the highest probability of being cost-
Table 3 Intermediate outcomes
Proportion correct
classification
Misclassification Test mortality Test
morbidity
Mortality
revascularization
Morbidity
revascularizationa
FPs FNs
Suspected CAD population
ICA–only 1 – – 0.00073 0.00064 0.00027 0.00047
NGCCT–ICA 0.9903 – 0.0097 0.00019 0.00018 0.00026 0.00044
NGCCT–only 0.8934 0.0969 0.0097 – – 0.00039 0.00067
Known CAD population
ICA–only 1 – – 0.0007 0.0006 0.0030 0.0051
NGCCT–ICA 0.9818 – 0.0182 0.0001 0.0003 0.0028 0.0048
NGCCT–only 0.9042 0.0775 0.0182 – – 0.0034 0.0058
a Stroke or MI due to the procedure
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effective if the cost-effectiveness threshold is less than
£70,000. For thresholds above £70,000, the three dif-
ferent strategies are more or less equivalent. However,
the probability of NGCCT–only being the cost-effective
strategy is still less than 50 % compared with the other
strategies, since the strategies have very similar total
costs and effects.
Known CAD population
Table 2 shows the cost-effectiveness results for the known
CAD population. The NGCCT strategies were more
effective than ICA–only in all subgroups. Overall
NGCCT–only was the most effective strategy (9.538
QALYs) compared to NGCCT–ICA (9.537 QALYs) and
ICA–only (9.516 QALYs). However, NGCCT–only was
also more expensive (£28,228) compared with NGCCT–
ICA (£27,785) leading to an ICER of £726,230 per QALY
gained. Consequently, NGCCT–ICA seems to be cost-ef-
fective for the known CAD population since the ICER of
NGGCT–only (£726,230) is considerably higher than the
threshold of £30,000 per QALY gained. When uncertainty
is taken into account, the above results still hold. The
acceptability curve graph (Fig. 6) shows that the NGCCT–
ICA strategy has the highest probability of being cost-ef-
fective independent of the willingness-to-pay thresholds,
while the ICA–only strategy has the smallest probability of
being cost-effective.
Fig. 6 Acceptability curves for
suspected and known CAD
populations. CAD coronary
artery disease, QALY quality
adjusted life years, ICA invasive
coronary angiography, NGCCT
new generation coronary
computed tomography
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Scenario analyses
The scenario analysis with a cost price of £150 for the
NGCCT did not affect the overall results; the NGCCT–ICA
strategy was still the most favourable strategy. However,
when the price of the NGCCT was increased to £207, the
ICA–only strategy became less expensive than the
NGCCT–only strategy for the known CAD population.
Varying the complication rates and the prior likelihood of
having CAD for the suspected population did not change
the overall results.
Discussion
64-slice CT has proven accuracy for the diagnosis of CAD in
most patients [2–4]. However, these scanners are less useful
for difficult-to-image patient groups, e.g. thosewith irregular
or fast heartbeats, those who are obese, or in whom artefacts
produced by high levels of coronary calcium or existing
stents might reduce image quality. Newer generation CT
scanners have the advantage of being capable of producing
diagnostic quality images in these patient groups. This study
has estimated the cost-effectiveness of new generation CT
scanners in these difficult-to-image patients.
For patients with suspected CAD, the NGCCT–only
strategy might be considered as cost-effective, since its
effectiveness is very similar to that of the most effective
strategy (difference: -0.009 QALYs) and since its overall
costs are much lower than those of the other strategies. For
patients with known CAD, a cost-effective strategy is
probably NGCCT followed by ICA if the NGCCT is pos-
itive (NGCCT–ICA), since it yields the highest cost-sav-
ing, and dominates the ICA–only strategy.
Several other studies have also concluded that little
differences in health outcomes across diagnostic strategies
exist [25–27]. Furthermore, it was concluded that coronary
CT angiography can be a cost-saving technique [26–28]
that can help to avoid unnecessary invasive angiograms
[27], although these results were found in studies evaluat-
ing the cost-effectiveness of 64-slice CT which has lower
accuracy estimates than NGCCT.
Strengths and limitations
The strength of this cost-effectiveness analysis is that we
were able to capture as well as possible the whole range of
patient experience from diagnostics to clinical pathway to
complications and radiation by combining economic model
components. Of course, combining evidence with the use
of economic models could be viewed as a limitation
because it introduces uncertainty and it was necessary to
make several assumptions. However, assumptions and
evidence sources have been explicitly reported and uncer-
tainty accounted for by probabilistic and scenario analyses.
The estimated accuracy of the NGCCT is based on the
accuracy of ICA, which was assumed to be 100 %. The use
of ICA as the gold standard is very common in this field
[2], but this may have influenced our results since the
estimated accuracy of the NGCCT is also based on the
accuracy of the ICA. In addition, ICA in combination with
fractional flow reserve is currently a frequently used pro-
cedure and can be considered to be a better alternative than
ICA–only [29]. Moreover, accuracy estimates for NGCCT
were only based on studies evaluating Somatom Definition
Flash, Discovery CT750 HD and Aquilion ONE, since
none of the studies evaluating the Brilliance iCT were
eligible for inclusion. Extrapolation of the cost-effective-
ness results to the other NGCCTs is therefore debatable.
Furthermore, the accuracy estimates of the NGCCT are
assumed to be the same for the known and suspected
population and do not differ between the different types of
NGCCT scanners. It is uncertain whether these assump-
tions may have led to an overestimate or an underestimate
of the cost-effectiveness of NGCCT–only and NGCCT–
ICA strategies.
The procedure costs of the NGCCT are estimated using
a micro-costing approach. Unfortunately, no data were
available on the consumables which are used during the
procedure. However, the extra cost per person to make the
NGCCT–only strategy not cost-effective vs the NGCCT–
ICA strategy in the suspected CAD population would have
to be about £80, given a willingness-to-pay threshold of
£30,000/QALY. In the known CAD population, the extra
cost would have to be over £1100 to make the NGCCT–
ICA strategy not cost-effective vs the ICA–only strategy
when a willingness-to-pay threshold of £30,000/QALY is
used.
The prior likelihood of CAD in the suspected CAD
population was based on the clinical guideline for chest
pain of recent onset [1] and for the known population it was
based on the prior likelihood estimated by the CE-MARC
study [7]. According to the clinical guideline, CT scans are
recommended for use in the diagnostic path of patients
with a prior likelihood of CAD of 10–29 % and a non-zero
calcium score [1]. This likelihood is based on presence of
certain clinical symptoms (suggestive of angina), age,
gender, diabetes, smoking and hyperlipidaemia. However,
scenario analyses showed that the overall results did not
change when the prior probability of patients suspected of
CAD increased. For the prior likelihood estimate in the
known CAD population, it is not entirely certain that the
CE-MARC study [7] and our study consider exactly the
same patient population. It is therefore possible that the
actual prior likelihood in our populations differs from that
currently assumed in our model.
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Complication rates for the initial procedures are a
compilation of various sources and are assumed to be the
same for all subgroups. This assumption may have led to an
inaccurate estimation of the MI and stroke rates for CABG,
percutaneous coronary intervention (PCI) and ICA.
Potential differences in any of these factors could lead to
different conclusions for the various NGCCTs. However,
we have performed scenario analyses changing the
parameters, which did not alter our conclusions.
Implications
The NICE recommendations about the use of these scan-
ners in the UK were based in part on the results of this
study. They recommended the use of new generation car-
diac CT scanners as an option for first line imaging of the
coronary arteries in patients with suspected CAD and for
first-line evaluation of disease progression to establish the
need for revascularization in patients with known CAD in
whom imaging with earlier generation CT scanners is
difficult [30]. However, the use of the less cost-effective
diagnostic strategy ICA shall remain a clinical option
despite its less favourable cost-effectiveness ratio [31].
According to this guideline it was estimated that the
number of people in England in whom imaging with earlier
generation CT scanners is difficult can range from 10 to
18 million [30].
The results of this analysis may differ by setting due to
differences in methodological, healthcare system or popu-
lation characteristics [32]. Methodological characteristics
including the perspective (e.g. societal) may not lead to a
substantially different ICER since the mean age of the
patients in most subgroups is above 60 and thus differences
in productivity costs between strategies can be considered
small. Most differences in costs and effects are incurred
immediately and thus varying discount rates may not have
a substantial impact. The intervention costs, prior likeli-
hood, severity of the CAD, the availability of health care
resources and clinical practice patterns are important
aspects that need to be considered when the transferability
of the results is assessed. However, the modelling methods
and input parameters are presented in a transparent and
reproducible way and therefore the developed model can
be adapted to other jurisdictions.
Conclusions
The use of NGCCT in difficult-to-image CAD patients
might be considered cost-effective based on the cost-ef-
fectiveness thresholds used in England and Wales. NGCCT
is equal in effectiveness to ICA but is cost-saving in both
the suspected CAD and the known CAD populations.
NGCCT is therefore recommended in the assessment of
patients who are difficult to image with earlier CT
scanners.
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